Aldeyra Therapeutics, Inc.
ALDX
$2.19
$0.188.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -47.30% | 21.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.73% | -10.39% | |||
| Operating Income | -2.73% | 10.39% | |||
| Income Before Tax | -4.60% | 10.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.60% | 10.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.60% | 10.30% | |||
| EBIT | -2.73% | 10.39% | |||
| EBITDA | -2.73% | 10.43% | |||
| EPS Basic | -4.49% | 10.47% | |||
| Normalized Basic EPS | -4.47% | 10.44% | |||
| EPS Diluted | -4.49% | 10.47% | |||
| Normalized Diluted EPS | -4.47% | 10.44% | |||
| Average Basic Shares Outstanding | 0.08% | 0.19% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.19% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||